Poster Session at ECC 2013 – Screening in colorectal cancer works
Discussion of the abstract by Professor Philippe Autier, Vice President, Population Studies, at the International Prevention Research Institute, Lyon, France.
Discussion of the abstract by Professor Philippe Autier, Vice President, Population Studies, at the International Prevention Research Institute, Lyon, France.
In recent years, there has been an adjustment in the scientific thinking about the utility of screening men for prostate cancer using prostate-specific antigen (PSA).
by Elizabeth C. Smyth, MB, BCh, MSc, and David Cunningham, MD, FRCP, FMedSci – In 2000, in order to optimise service provision for patients with cancer, 34 “Cancer… read more.
Taken from The Lancet – by Bruce Sylvester – Short-term folic acid supplement use does not affect overall cancer risk and does little to increase the risk of… read more.
by Ed Susman – Orlando, Florida – Researchers said they were surprised to find that prostate cancer patients treated with anticoagulants appear to achieve a longer median overall… read more.
As of 2009, the overall death rate for cancer in the United States had declined 20 percent from its peak in 1991, translating to the avoidance of approximately… read more.
Researchers have shown in the laboratory how a ‘transcription factor’ causes breast cancer cells to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond… read more.
Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a… read more.
A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences… read more.
Measurements taken over time of prostate specific antigen, the most commonly used screening test for prostate cancer in men, improve the accuracy of aggressive prostate cancer detection when… read more.
Magnetic resonance ultrasound fusion biopsy may aid in selection of patients for active surveillance versus aggressivetherapy, new study in The Journal of Urology® reports
There is no difference between proton radiotherapy (PRT) and intensity-modulated radiotherapy (IMRT) when comparing the toxicity among patients with prostate cancer at 12 months post-treatment according to a… read more.